IP analysis: The High Court held that Alexion’s patent for eculizumab, which claimed a light chain sequence including a 22-amino acid leader, was invalid and not infringed by biosimilars from Samsung Bioepis and Amgen. Although the biosimilars matched the therapeutic sequence of eculizumab, they lacked the leader sequence specified in the patent. Central to the dispute was whether the claimed sequence covered the clinically used eculizumab, which lacks the leader sequence. The court rejected Alexion’s purposive construction, and the claimants conceded the patent should be revoked on that basis. Even if infringement had been found, the patent would have failed for obviousness. The case underscores the importance of precise sequence drafting in biologic patents, especially where production processes remove non-functional regions. It shows the risks of relying on broad claim constructions that diverge from the literal sequence disclosed and used in practice. The multi-jurisdictional nature of these proceedings (including before the UPC) served to highlight deficiencies in Alexion’s case, where inconsistent arguments across different fora impacted on credibility. While decisions of other courts, including the UPC, should be brought before the UK court, they will not be material to the judge’s decision making. Written by Jennifer McDowall, associate at Pinsent Masons.